Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Lignende værker

• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  af: van Rhee, Frits, et al.
  Udgivet: (2010)
• TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3
  af: Shaughnessy, John D, et al.
  Udgivet: (2009)
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  af: Nair, Bijay, et al.
  Udgivet: (2010)
• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  af: Waheed, Sarah, et al.
  Udgivet: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  af: Hoering, Antje, et al.
  Udgivet: (2009)